/C O R R E C T I O N -- AstraZeneca/

/C O R R E C T I O N -- AstraZeneca/


In the news release, FDA Advisory Committee Recommends Further Data to Support
Approval of AstraZeneca's Oral Anticoagulant Exanta(R), issued earlier this
evening by AstraZeneca over PR Newswire, we are advised by the company that
following the third paragraph of the release there should be a fourth paragraph
reading:

"EXANTA is an investigational oral direct thrombin inhibitor (oral DTI) and is
poised to be the first oral anticoagulant since the development of warfarin
more than 50 years ago.  More than 30,000 patients in over 25 countries have
participated in the clinical trial program for EXANTA to date, with more than
17,000 patients receiving EXANTA.  EXANTA was studied as a fixed, oral dose
with no titration or coagulation monitoring," instead of being followed by the
paragraph headed, "About AstraZeneca," as originally issued inadvertently. 

PRNewswire -- Sept. 10 

DATASOURCE: AstraZeneca

Copyright